Vorinostat Plus Bevacizumab Had Activity in Previously Treated RCC

Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma.

Source: CancerNetwork - February 28, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news